Ensign Peak Advisors
AMPH icon

Ensign Peak Advisors’s Amphastar Pharmaceuticals AMPH Stock Holding History

Ensign Peak Advisors’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,900
Closed -$306K – 1802
2022
Q3 		$306K Hold
10,900
– – ﹤0.01% 1700
2022
Q2 		$379K Hold
10,900
– – ﹤0.01% 1575
2022
Q1 		$391K Hold
10,900
– – ﹤0.01% 1658
2021
Q4 		$254K Hold
10,900
– – ﹤0.01% 1870
2021
Q3 		$207K Hold
10,900
– – ﹤0.01% 1746
2021
Q2 		$220K Buy
10,900
+7,700
+241% +$145K ﹤0.01% 1712
2021
Q1 		$59K Buy
+3,200
New +$59.5K ﹤0.01% 1800

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ensign Peak Advisors's AMPH Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Amphastar Pharmaceuticals (AMPH) in Q4 2022, closing a stake of 10,900 shares — an estimated $306K sold.

Ensign Peak Advisors first reported a position in AMPH in Q1 2021 and held it in 7 quarters. The position peaked at $391K in Q1 2022. 211 funds tracked by Wall St. Rank hold AMPH as of Q4 2022.

  • Ensign Peak Advisors reported no remaining Amphastar Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 10,900 Amphastar Pharmaceuticals shares in Q4 2022, an estimated $306K.
  • Ensign Peak Advisors first reported a position in Amphastar Pharmaceuticals in Q1 2021 and held it in 7 quarters.
  • Ensign Peak Advisors's Amphastar Pharmaceuticals position peaked at $391K in Q1 2022.
  • 211 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.